Hikma Pharmaceuticals

Hikma Pharmaceuticals

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. 

About Hikma Pharmaceuticals

Latest Hikma Pharmaceuticals Share price

LON: HIK Dividends

Historical Data

Latest Hikma Pharmaceuticals News

Hikma Pharmaceuticals plc

Hikma Pharmaceuticals CEO Riad Mishlawi steps down, Executive Chairman assumes role

Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals reports 6% revenue growth and confirms FY outlook

Hikma Pharmaceuticals posted a 6% rise in H1 2025 revenue to $1.66 billion, supported by strong Injectables and Branded sales....
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals upgraded to ‘BBB’ by Fitch with stable outlook

Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and...
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals Plc delivers double digit revenue growth & increased profits in FY24

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025....
Hikma Pharmaceuticals plc

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities....
Hikma Pharmaceuticals plc

Hikma Pharmaceuticals PLC provides Trading Update and Future Growth Outlook

Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and...
Broker Ratings

Hikma Pharmaceuticals Plc 22.2% potential upside indicated by RBC Capital Markets

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 22.2% according to RBC Capital Markets.RBC Capital Markets...

Boardroom

Hikma Pharmaceuticals CEO Siggi Olafsson to step down

Hikma Pharmaceuticals PLC (LON:HIK) has announced that Siggi Olafsson has resigned as Chief Executive Officer, and from Hikma’s Board of...

Lab Testing

Hikma Pharmaceuticals achieves solid year-over-year increases in revenue and operating profit

Hikma Pharmaceuticals PLC (LON:HIK), the multinational pharmaceutical company, has reported its interim results for the six months ended 30 June...

Hikma

Hikma Pharmaceuticals receives FDA approval for KLOXXADO

Hikma Pharmaceuticals PLC (LON:HIK), the multinational pharmaceutical company, has announced the approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, by...

Hikma Pharmaceuticals

Hikma Pharmaceuticals resumes the launch of its generic version of GSK’s Advair Diskus

Hikma Pharmaceuticals PLC (LON:HIK), the multinational pharmaceutical company, has announced that it has resumed the launch of its generic version...

Hikma Pharmaceuticals deliver strong H1 results with core group revenue up 9%

Hikma Pharmaceuticals PLC (LON:HIK), the multinational pharmaceutical company, has reported its interim results for the six months ended 30 June...

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.